Abstract
. anesthetized, open-chest dogs ET-1 Groups 1 and 2: 11 and 33 pmol P kg P min ; n s 6 and 6, respectively or physiological saline Ž . Group 3, n s 5 were infused into the closed pericardial sac for 40 min. In serial pericardial fluid and aortic blood plasma samples, ET-1 Ž . levels were measured by radioimmunoassay, and analysed by high-performance liquid chromatography HPLC . Systemic arterial blood Ž . Ž . pressure, heart rate, cardiac output CO , standard ECG and right ventricular endocardial monophasic action potentials MAPs were Ž recorded. Results: Basal pericardial fluid ET-1 levels were significantly higher than respective plasma levels 342 " 210 vs. 8.0 " 5.2 pmol P l y1 , n s 14, P -0.001. In HPLC analysis pericardial fluid ET-1 was indistinguishable from ET-1 . Infusion of exogenous 1 -21 ET-1 into the pericardial space induced ventricular arrhythmias in all instances, which were associated with 9.7-fold increase in pericardial fluid ET-1 levels. Ventricular tachycardias developed in 9 of 12 animals. The arrhythmogenic effect of ET-1 was more Ž apparent in dogs with the larger dose. Before the onset of arrhythmias, intrapericardial infusion of ET-1 increased QT time Group 1:
. Ž 207 " 18 to 230 " 23 ms, P -0.01; Group 2: 220 " 12 to 277 " 17 ms, P -0.01 and MAP duration at 90% repolarization at 300 ms . Ž . cycle length Group 1: 192 " 9 to 216 " 9 ms, P -0.01; Group 2: 205 " 9 to 255 " 9 ms, P -0.001 . Hemodynamic variables did not change significantly prior to the onset of ventricular tachyarrhythmias. In Group 3, arrhythmias were not observed and all electrophysiological and hemodynamic parameters remained unchanged. Conclusions: Administration of exogenous ET-1 into the pericardial space induces ventricular arrhythmias associated with prolongation of QT time and MAP duration. Whether pericardial fluid ET-1 under pathophysiological conditions can ever reach sufficiently high levels to induce ventricular arrhythmias remains to be elucidated. q 1998 Elsevier Science B.V. All rights reserved.
Introduction

Ž .
Endothelin ET , the most potent vasoconstrictor peptide known so far, was originally characterized from the w x supernatant of cultured porcine aortic endothelial cells 1 .
( )being directed toward the interstitial region rather than the w x vascular lumen 3 , suggesting that ET-1 acts as a local autocrine and paracrine factor rather than as a circulating hormone. ET-1, produced by vascular endothelium, appears to be a significant factor in the regulation of smooth w x muscle tone 2 . Moreover, ET-1 released by the endocardial endothelium has recently been shown to influence myocardial contractile state of the subjacent cardiomyw x ocytes 4,5 . In contrast to the vascular and endocardial endothelia, less attention has been paid to the physiological significance of the pericardium, which is lined with mesothelial cells, derived from the same stem cells as w x vascular endothelial cells 6,7 . In vitro, epicardial w x mesothelial cells synthesize and release ET-1 8 . We have reported recently that pericardial fluid of human subjects with heart disease contains extremely high concentrations of ET-1, suggesting that epicardial secretion of the peptide w x into the pericardial fluid may occur in vivo 9 . However, no information is available whether or not high pericardial fluid ET-1 levels can influence cardiac function.
ET-1 has multiple actions in the heart. The peptide exerts potent coronary vasoconstrictor, and moderate inw x otropic and chronotropic effects 10-14 , and induces hyw x pertrophy of cardiomyocytes 15,16 . In addition, accumulating evidence suggests that ET-1 may have direct arrhythmogenic effect. In isolated ventricular myocytes, ET-1 increases the action potential duration and is capable of Ž . w x inducing early afterdepolarizations EADs 17 . In anesthetized dogs, intracoronary administration of ET-1 at low concentrations, which reduces coronary blood flow only slightly, induces severe ventricular arrhythmias accompanied by the prolongation of monophasic action potential w x duration and the development of EADs 18,19 .
The aim of the present study was to characterize ET-1 levels in plasma and pericardial fluid and to study the potential pathophysiological effects of local high concentrations of the peptide by infusing ET-1 into the closed pericardial sac of anesthetized dogs.
Methods
Animal preparation
Acute experiments were conducted in mongrel dogs Ž . n s 17 of either sex weighing 13-24 kg. Each animal was anesthetized with intravenous sodium pentobarbital Ž . 30 mgrkg and supplemental doses were given throughout the experiment as needed to maintain constant level of anesthesia. An endotracheal tube was inserted, and the dogs were artificially ventilated with room air using a Ž . volume cycled respirator Cape Eng., UK . Catheters were inserted into the abdominal aorta through both femoral arteries, one of them connected to a pressure transducer Ž . model P23 ID, Gould Electronics, USA for arterial blood pressure monitoring, and the other serving for arterial blood sampling. 
Experimental protocol
After a 30-min period of stabilization, exogenous ET-1 Ž . Sigma Chemical, St. Louis, MO, USA was administered as a continuous infusion into the closed pericardial sac at a flow rate of 0.25 ml P min y1 for 40 min, followed by 120 Ž . min recovery. In animals of Group 1 n s 6 and Group 2 Ž . n s 6 , ET-1 was infused at a rate of 11 and 33 pmol P kg y1 P min y1 , respectively. Animals of time control group Ž . Ž . n s 5 received vehicle physiological saline infusion according to the same protocol. Hemodynamic parameters including systemic arterial blood pressure, sinus heart rate and cardiac output were measured at baseline and repeated Ž at 10-min intervals. Surface ECG leads I, II, III, aVR, . aVL, aVF and endocardial MAPs were recorded continuously for arrhythmia analysis and for detection of EADs, respectively. The following electrophysiological parame-( )ters were determined at baseline and thereafter at 10-min intervals until the appearance of severe rhythm disturbances: cycle length, PQ interval for AV conduction time, QRS duration, and QT time. The QT interval was determined mainly from ECG lead II and was defined as the time between QRS onset and the point at which the line of maximal downslope of the T wave crossed the baseline. Three consecutive beats were measured and averaged at all time points. For electrophysiological studies the programmed electrical stimulation of the right ventricle was performed at basal state and repeated at 10-min intervals Ž by using an impulse generator UHS-20, Biotronik, Ger-. Ž . many . Electrical impulses 2.0 ms in duration were delivered at twice the diastolic myocardial threshold. Ventricu-Ž . lar effective refractory period VERP was determined by using ventricular pacing via the MAP electrodes at cycle Ž . length S1S1 of 300 ms for eight beats followed by an Ž . extrastimulus S2 with decremental delay until the extrastimulus failed to produce response, which was taken as VERP. The duration of MAP was determined at 90% Ž . repolarization MAPD , which included EADs if present.
90
MAPD was measured at 300 ms cycle length using only 90 data from recordings with stable resting potentials. Three consecutive MAP signals were analyzed manually for MAPD and then averaged at all time points. EADs were 90 w x defined according to Cranefield 21 and Damiano and w x Rosen 22 as depolarizing afterpotentials that interrupted or delayed repolarization of the action potential. The irritability of the ventricles was tested by using single or double early stimuli and bursts of rapid pacing at a rate of Ž . 300 per min 20 beats per burst . Arrhythmias were analysed from ECG recordings. Non-sustained ventricular tachycardia was defined as four or more consecutive ventricular premature beats lasting less than 30 s. Sustained ventricular tachycardia was defined as 100 or more consecutive ventricular extrabeats, or tachycardia persisting for more than 30 s. Pericardial fluid and plasma samples were collected for ET-1 determination at baseline and after the end of infusion period in 10-min intervals until a marked decline in the number and severity of arrhythmias were observed. The latter samples were collected to estimate Ž ET-1 levels at the peak of arrhythmia induction ca. [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] . min after the start of the experiments . All samples were immediately placed on dry ice and stored at y208C until assayed.
Extraction procedures
Plasma and pericardial fluid samples were extracted utilising SepPak C18 cartridges as described elsewhere w x 23 . Briefly, 1 ml plasma and 200-500 ml pericardial fluid samples were acidified to pH 4 with 10% trifluoroacetic acid and applied to SepPak C18 cartridges previously activated by methanol and triethanolamine acetate Ž
y1
. buffer TEA, 20 mmolP l , pH 4 . The peptide was eluted with 80% methanol in TEA buffer. Eluates were evaporated and reconstituted in RIA buffer containing Na PO 3 4 Ž y1 . Ž y1 . 0.1 mol P l , NaCl 0.05 mol P l and Triton X-100 Ž . 0.1% vrv . Recovery of added ET-1 was 80 " 2%. Duplicates of 100-ml aliquot fractions from the above dilution were assayed for ET-1 using RIA.
Determination of ET-1-like immunoreactiÕity
Plasma and pericardial fluid ET-1 levels were measured Ž . utilizing antiserum RAS 6901N purchased from Penin-Ž . sula Laboratories Mersyside, UK . Human ET-1 1 -21 Ž . Sigma Chemical, Germany ranging from 0 to 80 pmol P l y1 per tube was used to construct the standard curve. Radioiodinated ET-1 was produced using the chloramine-T method. The sensitivity of the assay was 0.3 pmol P l y1 per tube. The 50% intercept of the standard curve was at 7.2 pmol P l y1 per tube, intra-and interassay coefficients of variation were less than 10% and 15%, respectively.
( ) 2.5. High-performance liquid chromatography HPLC
For HPLC analysis lyophilized pericardial fluid samples were redissolved in 40% acetonitriler0.1% trifluoroacetic acid in water and applied onto a 7.8 = 300 mm ProteinPak Ž 125 gel filtration HPLC column Waters, Milford, MA, . USA and eluted with the same solvent. Fractions were collected every 30 s, evaporated and then dissolved in RIA buffer and measured in ET-1 RIA.
Statistical analysis
The results are expressed as mean " s.e.m. Since ET-1 values were not normally distributed, these are presented as mean " s.d. and range. Statistical significance of the differences was tested with ANOVA, paired t-test, Wilcoxon signed-ranks test or independent-groups t-test, when appropriate. To assess correlation between data Spearman's rank correlation was used. Differences were considered statistically significant at the level of P -0.05.
Results
Effects of intrapericardial administration of ET
. Infusion of ET-1 11 and 33 pmol P kg P min into the pericardial space for 40 min induced ventricular ar-Ž . rhythmias in all instances n s 12 , whereas upon saline Ž . infusions Group 3, n s 5 arrhythmias could not be detected. The arrhythmogenic effect of ET-1 is summarized Ž in Table 1 . In Groups 1 and 2, ET-1 infusion n s 6 and 6, . respectively induced substantial number of ventricular extrasystoles, couplets and triplets with onset at 10 to 20 Ž . min Fig. 1 . The increasing number of ventricular extrabeats were followed by non-sustained ventricular tachycardias in three instances in Group 1, whereas in all instances in Group 2. At 30 to 50 min, ET-1 induced non-sustained ventricular tachycardias regularly followed each other in an incessant manner. In Group 2, ET-1 induced sustained Ž ventricular tachycardias in four of six animals Table 1 † P -0.01 and ‡ P -0.001 vs.
control group; a P -0.05 and § P -0.01 vs. group receiving ET-1 infuy1 y1 Ž . sion at a rate of 11 pmolPkg Pmin independent-groups t-test .
one instance. The arrhythmias lasted for 70 to 130 min, and thereafter spontaneously disappeared in all instances except when ventricular fibrillation terminated the experiments. Fig. 3 . Moreover, the Ž prolongation of MAPD was significantly greater P - Hemodynamic parameters were measured at baseline and 20 min after the start of ET-1 Group 1: 11 pmolPkg Pmin , ns6; Group 2: 33 y1 y1
Electrophysiological and hemodynamic parameters
. Ž . pmolPkg Pmin , ns6 or vehicle infusions Group 3, ns 5 . In ET-1-treated animals, 20 min represents a time point prior to the onset of severe arrhythmias. MABPs mean arterial blood pressure; COs cardiac output; SVR ssystemic vascular resistance; HR s heart rate. Values are expressed as mean"s.e.m.
in two of three instances EADs developed in both record-Ž . ings Fig. 4 .
As shown in Table 3 , hemodynamic parameters remained unchanged when saline was infused into the closed Ž y1 . pericardial sac at a low infusion rate 0.25 ml P min . Intrapericardial infusion of ET-1 also did not induce significant change in blood pressure, cardiac output, systemic vascular resistance and heart rate prior to the onset of Ž . ventricular arrhythmias Table 3 . The hemodynamic changes were also insignificant when compared with the saline time control group. At 50-60 min, development of ventricular tachyarrhythmias was followed by significant decrease of cardiac output and increase of systemic vascu-Ž . lar resistance data not shown .
Plasma and pericardial fluid ET-1 leÕels
As shown in Fig. 5A , basal pericardial fluid ET-1 levels Ž
y1
. 342 " 210 pmol P l , range: 139-958, n s 14 were sig-Ž . nificantly higher P -0.001 than respective plasma levels Ž y1 . 8.0 " 5.2 pmol P l , range: 1.9-22 . Of note is that in one animal the concentration of pericardial fluid ET-1 was extremely high exceeding 3 s.d., therefore this value has Ž . ET-1 infusion into the pericardial space increased basal Ž pericardial fluid ET-1 levels 9.7-fold from 387 " 242 to
. 3772 " 2639 pmol P l , P -0.01, n s 9 , measured at the peak of arrhythmia induction, whereas, plasma ET-1 levels Ž remained practically unaltered from 8.7 " 6.4 to 8.7 " 4.7
. pmol P l , P s n.s., n s 9 . In the saline time control Ž group neither pericardial fluid from 261 " 118 to 155 " 28 y1 . pmol P l , P s n.s., n s 5 , nor plasma ET-1 levels were Ž affected significantly from 7.6 " 1.2 to 7.8 " 2.8 pmol P y1 . l , P s n.s., n s 5 .
Discussion
In the present study we were able to show the presence of immunoreactive ET-1 in the pericardial fluid of dogs. In HPLC, pericardial fluid ir-ET-1 was indistinguishable from ET-1
. Concentrations of ET-1 in the pericardial fluid 1 -21 are far higher than in any biological fluids tested thus far, w x w x including plasma, urine 24 , saliva 25 , and cerebrospinal w x fluid 26 . Previously we have reported that high ET-1 levels can be found in the pericardial fluid of patients w x undergoing cardiac surgery 9 . The pericardial fluid to plasma ratio of ET-1 was comparable in humans and dogs Ž . 36 " 12 versus 79 " 31 , suggesting that the presence of high ET-1 levels in the pericardial fluid is a physiological phenomenon, at least in some species, and can not be related exclusively to disease state.
Analysis of protein and ion composition of pericardial fluid indicates that it is mainly formed as a passive ultrafilw x trate of blood plasma 27 ; however, the high pericardial fluid to plasma ratio of ET-1 seems to suggest that the major site of origin of this peptide in the pericardial fluid cannot be the blood plasma. Since epicardial mesothelial w x cells have been shown to secrete ET-1 in vitro 8 , it is tempting to speculate that pericardial fluid ET-1 originates from the epicardium itself.
( )Pericardial fluid partially originates as an overflow of w x myocardial interstitial fluid 27 , suggesting that substances released by cardiac myocytes into the interstitial space can be translocated into the pericardial compartment with the flow of interstitial fluid. Several experimental data suggest that substances administered at the external surface of the epicardium can be translocated into the myocardial interstitium. Page et al. demonstrated that distension of isolated rat atrial preparation at pressures prevailing in vivo, renders atrial epicardium and myocardium permeable even to Ž .w x large molecules 40 to 500 kDa 28 . Polypeptides such as substance P have been reported to be rapidly absorbed w x through the epicardium 29 . In perfused rabbit atria, radiolabelled inulin, which has similar molecular weight to ET-1, introduced into the pericardial space is translocated with the flow of interstitial fluid through the myocardium w x into the atrial lumen upon stretch and release 30 . Prostaglandins have been reported to modulate cardiac autonomic neurotransmission when applied in a canine w x epicardial superfusion model 31 . Intrapericardial injection of basic fibroblast growth factor and heparin sulfate induced angiogenesis and myocardial salvage in a canine w x model of myocardial infarction 29 . Previously, epicardial mesothelial cells have been shown to modify the phenotype and function of adult rat ventricular cardiomyocytes w x in primary coculture 32 . Later, it was proposed that ET-1 may take part in epicardial mesothelial cell-cardiomyocyte w x interaction 8 . In vivo, ET-1 released by mesothelial cells may accumulate in the pericardial fluid and may be transported into the myocardial interstitial space. Upon binding to specific endothelin receptors located on the surface of w x cardiomyocytes 33 , ET-1 can influence cardiac function and myocyte phenotype.
An accumulating body of evidence suggests that ET-1 may have a direct arrhythmogenic effect. In anesthetized dogs, intracoronary administration of ET-1 at low concentrations, which reduces coronary blood flow only slightly, induces severe ventricular arrhythmias that commonly dew x generate into ventricular fibrillation and death 34,18 . Our present results showed that ET-1, when applied intrapericardially, could also evoke major ventricular arrhythmias. The tachyarrhythmias were always preceded by prolongation of QT interval and monophasic action potential duration, in a similar manner as was reported previously upon w x intracoronary administration of ET-1 18,19 . Development of EADs could be detected in more than 50% of dogs, suggesting that the arrhythmias could be of triggered oriw x gin 35,36 ; however, the involvement of other mechanisms cannot be ruled out.
In canine cardiac tissues, it has been shown that ET-1 increases the action potential duration and is capable of w x 2q inducing EADs 17 . Nicardipine, a Ca channel blocker, abolished the development of EADs and shortened the ET-induced action potential prolongation, suggesting the involvement of dihydropyridine-sensitive Ca 2q channels w x 17 . Since patch-clamp studies have established that ET-1 q w x inhibits the ATP-sensitive K current 37 and the delayed q w x rectifier K current in ventricular myocytes 38,39 , it is conceivable that in addition to Ca 2q channels K q channels may also be involved in the arrhythmogenic effect of ET-1. However, the cellular mechanisms underlying the arrhythmias induced by intrapericardial application of ET-1 remain to be established.
In the present study, underlying myocardial ischemia cannot be ruled out; however, several lines of evidence suggest that ET-1 may have direct arrhythmogenic effect upon intrapericardial administration. First, modest if any ischemic signs could be detected on ECG; however, severe ventricular arrhythmias were observed. Previously, Hori et al. have reported that epicardial application of ET-1 induces subepicardial microischemia formation, which is accompanied by sustained epicardial ST-segment elevation w x 40 . Second, prolongation of QT interval and MAPD 90 occurred in every instance, whereas ischemia per se leads w x to the shortening of MAP duration 41 . Third, in dogs, upon intracoronary administration of ET-1, significant coronary vasoconstriction occurred in association with substantial increase in coronary sinus and aortic blood plasma Ž . ET-1 levels 175-fold and 6-fold increase, respectively w x 42 , whereas in the present study there was no increase in arterial ET-1 concentrations. Finally, in the absence of significant hemodynamic changes prior to the onset of arrhythmias, severe myocardial ischemia as the sole mechanism of ET-1-induced arrhythmias is unlikely.
Clinical conditions such as cardiac hypertrophy and failure are associated with high risk of sudden death, believed in most cases secondary to ventricular tachw x yarrhythmias 43 . Myocardial hypertrophy has been shown to lengthen transmembrane action potential duration and to w x increase their dispersion 44 , producing an electrophysiological milieu which may facilitate the development of w x arrhythmias 45 . In the hypertrophied and failing myocardium the production of ET-1 is markedly increased and the density of myocardial ET receptors is elevated w x 46-48 . ET expression in cardiac hypertrophy may be induced by several stimuli, including mechanical stretch w x 49,50 produced by cardiac overload, increased activity of w x the intracardiac renin-angiotensin system 51 and the induction of myocardial expression of transforming growth w x factor-b 52 . It is feasible that the factors responsible for the upregulation of the myocardial ET system may also induce the synthesis of ET-1 in epicardial mesothelial cells and increase pericardial fluid ET-1 concentrations. In support of this hypothesis, angiotensin II has been shown to stimulate ET-1 release of epicardial mesothelial cells in w x vitro 8 . Taken together, we propose that in cardiac hypertrophy and failure in the presence of multiple arrhythmogenic factors, including structural abnormalities, elevated catecholamine levels, electrolyte abnormalities and prolongation of the cardiac action potential, high concentrations of pericardial fluid ET-1, in conjunction with the upregulated myocardial ET system, may take part in the initiation ( )of ventricular tachyarrhythmias leading to sudden cardiac death.
In summary, our results show for the first time that administration of ET-1 into the pericardial space, increasing basal pericardial fluid ET-1 levels 9.7-fold, induces severe ventricular arrhythmias. Our results suggest that the arrhythmogenic effect of ET-1 may be based on prolongation of QT interval and monophasic action potential duration. Previously, high ET-1 levels have been reported in w x the pericardial fluid of patients with heart failure 9 , a clinical condition associated with high risk of occurrence w x of ventricular tachyarrhythmias 43 . Under pathophysiological states such as cardiac hypertrophy and failure accompanied by an electrophysiological milieu that may w x facilitate the development of rhythm disturbances 45 , high concentrations of pericardial fluid ET-1 may be involved in the induction of ventricular tachyarrhythmias and sudden cardiac death. Whether pericardial fluid ET-1 in these clinical conditions can ever reach sufficiently high levels to induce ventricular arrhythmias remains to be elucidated.
